Trial · NCT00030771
Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients
NCT00030771, Phase 3, Completed, Swiss Cancer Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients. Trials, record NCT00030771. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00030771
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients
- NCT number
- NCT00030771
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 232 participants, actual
- Lead sponsor
- Swiss Cancer Institute
- Conditions
- Lung Cancer
- Interventions
- Chemotherapy, Radiotherapy, Surgery
- First posted
- 2003-01-27
- Last updated
- 2024-01-17
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Event-free survival | 1 month after surgery | Time from randomization to relapse/progression/second tumor/death, whichever occurs first (for all randomized patients). If no event is observed, the patients will be censored at the last time they were known to be alive. |
| Secondary | Postoperative mortality assessed | 1 month after surgery | All deaths occurring within 30 days of the thoracic surgery to remove the primary tumor |
| Secondary | Toxicity (hematological, renal and neurological toxicities, nausea and vomiting, weight changes as well as esophageal toxicities) | During treatment | Assessed according to the NCIC-CTG Expanded Common Toxicity Criteria grading. Special attention shall be given to hematological, renal and neurological toxicities, nausea and vomiting, weight changes as well as esophageal toxicities. |
| Secondary | Complete resection rate after surgery | 1 month after surgery | Assessed according to the NCIC-CTG Expanded Common Toxicity Criteria grading. |
| Secondary | Objective response rate measured after completion of chemoradiotherapy | 43 days | Response rate will be evaluated according to the 1. WHO response criteria 2. TNM classification after surgery. |
| Secondary | Operability | 1 month after chemo | Patients who are able to undergo radical resection of their lung cancer after neoadjuvant therapy, as assessed by the thoracic surgeon. |
| Secondary | Overall survival | Life-long follow-up until death of patient (up to 30 years) | Calculated from randomization to the date of death from any cause. Patients not experiencing an event will be censored at the last time they were known to be alive. |
| Secondary | Failure pattern | Life-long follow-up until death of patient (up to 30 years) | Defined as location of first tumor progression or relapse. Failure can be local relapse (area of primary tumor or mediastinum), distant relapse (all others) or the combination thereof. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00030771
GET https://conductscience.org/api/trials/v1/NCT00030771/registered